Article
Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Trials - 10 Apr 2015
Yang Xiao-Bing, Wu Wan-Yin, Long Shun-Qin, Deng Hong, Pan Zong-Qi, He Wen-Feng, Zhou Yu-Shu, Liao Gui-Ya, Li Qiu-Ping, Xiao Shu-Jing, Cai Jiao-Zhi
Abstract excerpt
BACKGROUND: Patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) gene respond well to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. Chinese herbal medicine (CHM) has been used as a complementary therapy for cancer for d...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.